三阴性乳腺癌免疫微环境与免疫治疗的研究进展  

Advance in immune microenvironment and immunotherapy in triple-negative breast cancer

作　　者：胡月 王稼良 胡飞翔 高荣 洪波[1] HU Yue;WANG Jialiang;HU Feixiang;GAO Rong;HONG Bo(Medical Pathology Center,Hefei Cancer Hospital,Chinese Academy of Sciences,Hefei,Anhui 230000,China;不详)

机构地区：[1]中国科学院合肥肿瘤医院医学病理中心,安徽合肥230000 [2]复旦大学附属肿瘤医院放射诊断科,上海200032 [3]安徽医科大学基础医学院,安徽合肥230032

出　　处：《中国临床研究》2024年第10期1477-1482,共6页Chinese Journal of Clinical Research

基　　金：国家自然科学基金(81872438);中国科学院合肥肿瘤医院“优秀医学青年人才计划”项目(YQJH2022010)。

摘　　要：乳腺癌是最常见的女性恶性肿瘤,三阴性乳腺癌(triple-negative breast cancer,TNBC)是最具侵袭性的乳腺癌亚型,其特征是分化差、进展率高、预后差。由于缺乏生物标志物,针对TNBC患者的靶向治疗选择有限,目前化疗、放疗和手术切除是其主要治疗方式。由于TNBC具有高肿瘤突变负荷和高浸润密度的肿瘤浸润淋巴细胞,可以从免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)的治疗中受益。本文重点概述ICIs在TNBC中的研究,旨在为TNBC患者治疗提供相应理论依据。Breast cancer is the most common malignant tumor in women.Triple-negative breast cancer(TNBC)is the most aggressive subtype of breast cancer,characterized by poor differentiation,high rate of progression and poor prognosis.Due to the lack of biomarkers,targeted therapy options for patients with TNBC are limited,and chemotherapy,radiotherapy,and surgical resection are currently the main treatment modalities.Since TNBC has a high tumor mutation burden and a high infiltration density of tumor-infiltrating lymphocytes,it may benefit patients from the treatment of immune checkpoint inhibitors(ICIs).This article focuses on the research of ICIs in TNBC,aiming to provide corresponding theoretical basis for the treatment of TNBC patients.

关 键 词：三阴性乳腺癌 免疫微环境 免疫治疗 免疫检查点抑制剂 程序性死亡受体1 程序性死亡受体-配体1 细胞毒性T淋巴细胞相关抗原-4 

分 类 号：R737.9[医药卫生—肿瘤]